1-7 of 7
Ying Huang
Close
Sort by
Journal Articles

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2 -mutant AML

Clinical Trials & Observations
Sheng F. Cai, Ying Huang, Jennie R. Lance, Hsiaoyin Charlene Mao, Andrew J. Dunbar, Samantha N. McNulty, Todd Druley, Yan Li, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William G. Blum, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark Litzow, Tara Lin, Prapti Patel, Matthew C. Foster, Michael Boyiadzis, Robert H. Collins, Jordan Chervin, Abigail Shoben, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Timothy L. Chen, Ashley O. Yocum, Franchesca Druggan, Sonja Marcus, Mona Stefanos, Brian J. Druker, Alice S. Mims, Uma Borate, Amy Burd, John C. Byrd, Ross L. Levine, Eytan M. Stein
Journal: Blood Advances
Blood Adv (2024) 8 (2): 429–440.
https://doi.org/10.1182/bloodadvances.2023010563
Published: 2024
Includes: Supplemental data
Journal Articles

Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization

Samantha M. Teierle, Ying Huang, Adam S. Kittai, Seema A. Bhat, Michael Grever, Kerry A. Rogers, Weiqiang Zhao, Daniel Jones, John C. Byrd, Matthew R. Avenarius, Nyla A. Heerema, Jennifer A. Woyach, Cecelia R. Miller
Journal: Blood Advances
Blood Adv (2023) 7 (23): 7239–7242.
https://doi.org/10.1182/bloodadvances.2023010753
Published: 2023
Includes: Supplemental data
Journal Articles

Racial and socioeconomic disparities in CLL/SLL: analysis of SEER data from 2006 to 2019

Adam S. Kittai, Ying Huang, Seema A. Bhat, Electra D. Paskett, Kerry A. Rogers, Jacqueline C. Barrientos, James L. Fisher, Jennifer A. Woyach
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2575–2579.
https://doi.org/10.1182/bloodadvances.2022008643
Published: 2023
Journal Articles

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes

Clinical Trials & Observations
Jonathan M. Hyak, Ying Huang, Kerry A. Rogers, Seema A. Bhat, Michael R. Grever, John C. Byrd, Adam S. Kittai, Dan Jones, Cecelia R. Miller, Jennifer A. Woyach
Journal: Blood Advances
Blood Adv (2022) 6 (17): 5124–5127.
https://doi.org/10.1182/bloodadvances.2022007708
Published: 2022
Includes: Supplemental data
Journal Articles

Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas

Clinical Trials & Observations
Megan Fleming, Ying Huang, Emily Dotson, David A. Bond, John Reneau, Narendranath Epperla, Lapo Alinari, Jonathan Brammer, Beth A. Christian, Robert A. Baiocchi, Kami Maddocks, Yazeed Sawalha
Journal: Blood Advances
Blood Adv (2022) 6 (2): 460–472.
https://doi.org/10.1182/bloodadvances.2021005999
Published: 2022
Journal Articles

Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists

Clinical Trials & Observations
Kristin L. Koenig, Ying Huang, Emily K. Dotson, Shane Sheredy, Seema A. Bhat, John C. Byrd, Emily Desmond, Jill Ford, Shauna Iarocci, Jeffrey A. Jones, Margaret S. Lucas, Mollie E. Moran, Tracy E. Wiczer, Jennifer A. Woyach, Farrukh T. Awan, Kerry A. Rogers
Journal: Blood Advances
Blood Adv (2020) 4 (19): 4860–4863.
https://doi.org/10.1182/bloodadvances.2020002593
Published: 2020
Includes: Supplemental data
Journal Articles

Human MYD88 L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells

Tomasz Sewastianik, Maria Luisa Guerrera, Keith Adler, Peter S. Dennis, Kyle Wright, Vignesh Shanmugam, Ying Huang, Helen Tanton, Meng Jiang, Amanda Kofides, Maria G. Demos, Audrey Dalgarno, Neil A. Patel, Anwesha Nag, Geraldine S. Pinkus, Guang Yang, Zachary R. Hunter, Petr Jarolim, Nikhil C. Munshi, Steven P. Treon, Ruben D. Carrasco
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3360–3374.
https://doi.org/10.1182/bloodadvances.2019000588
Published: 2019
Includes: Supplemental data